4,021 Shares of Jazz Pharmaceuticals PLC $JAZZ Bought by International Assets Investment Management LLC

International Assets Investment Management LLC acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 4,021 shares of the specialty pharmaceutical company’s stock, valued at approximately $931,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in JAZZ. USA Financial Formulas acquired a new position in shares of Jazz Pharmaceuticals during the 1st quarter valued at about $25,000. Pension & Wealth Management Advisors Inc. acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at $32,000. Ameritas Advisory Services LLC acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at $47,000. Westpac Banking Corp purchased a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at $51,000. Finally, Root Financial Partners LLC raised its holdings in shares of Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after buying an additional 89 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat Q3 revenue and earnings expectations, with growth in oncology and rare sleep products cited as drivers. The company raised its 2026 revenue outlook to roughly $4.78 billion–$4.85 billion, above the prior consensus near $4.7 billion. Q3 earnings and outlook
• Positive Sentiment: The company announced a $500 million share buyback, which may support shareholder returns and provide demand for the stock. Share buyback announcement
• Positive Sentiment: Several analysts raised their price targets and maintained bullish ratings after the results, including JPMorgan, Morgan Stanley, RBC and Barclays. Analyst insights
• Neutral Sentiment: Director Bruce Cozadd sold 6,000 shares under a pre-arranged Rule 10b5-1 plan, reducing his position by 1.73%; he retained 339,875 shares after the sale. SEC filing
• Negative Sentiment: Some coverage cautioned that slowing growth and an Actiq-related charge could temper the positive effect of the earnings beat and improved guidance. Earnings outlook risks

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on JAZZ shares. TD Cowen raised their target price on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Royal Bank Of Canada increased their price target on shares of Jazz Pharmaceuticals from $296.00 to $305.00 and gave the stock an “outperform” rating in a research report on Tuesday. UBS Group lifted their price objective on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a “buy” rating in a report on Friday, September 11th. Piper Sandler lifted their price objective on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Finally, Citigroup assumed coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, September 30th. They set a “buy” rating and a $325.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $293.45.

Insider Activity

In related news, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $240.94, for a total value of $289,128.00. Following the transaction, the executive vice president owned 47,671 shares of the company’s stock, valued at $11,485,850.74. This represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $215.84, for a total value of $1,295,040.00. Following the completion of the sale, the director owned 339,875 shares in the company, valued at approximately $73,358,620. This represents a 1.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 100,121 shares of company stock valued at $24,632,962 over the last quarter. Company insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $234.66 on Thursday. The stock’s 50-day moving average is $230.15 and its two-hundred day moving average is $217.11. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.82 and a quick ratio of 1.58. Jazz Pharmaceuticals PLC has a 1-year low of $128.80 and a 1-year high of $266.38. The company has a market cap of $15.06 billion, a price-to-earnings ratio of 79.82, a price-to-earnings-growth ratio of 0.46 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter last year, the business posted $8.13 EPS. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. Analysts forecast that Jazz Pharmaceuticals PLC will post 10.84 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.